Uncharged lipid delivery systems for gene therapy
Innovative uncharged lipid systems enhance gene therapy delivery by mimicking natural lipids, offering improved biocompatibility, stability, and reduced toxicity. Suitable for mRNA, DNA, siRNA, and CRISPR-Cas9 delivery, these systems overcome limitations of traditional lipid nanoparticles.
Overview
Uncharged lipid delivery systems represent a breakthrough in gene therapy, offering a biocompatible and stable alternative to traditional lipid nanoparticles (LNPs). These systems are designed to mimic naturally occurring lipids, which improves their transfection efficiency and biocompatibility. Unlike conventional LNPs, uncharged lipids eliminate the need for ionizable, hygroscopic, and PEGylated lipids, reducing the systemic effects and enhancing redosing capabilities. These systems are particularly suited for delivering large nucleic acids such as mRNA and DNA (>15 kb), as well as other therapeutic cargos like siRNA and CRISPR-Cas9.
Technical specifications
- Biomimetic design: Resembling natural lipids, uncharged systems enhance coordination with nucleic acids, overcoming oxidation and degradation issues.
- Stable headgroups: Provide stability across pH ranges, ensuring effective hydrogen bonding with nucleic acids.
- Enhanced delivery mechanisms: Promote uptake via micropinocytosis and controlled endosomal escape, enabling prolonged circulation and targeted organ delivery.
- Reduced toxicity: Lower systemic effects, improved cellular uptake, and avoidance of recycling pathways seen in traditional LNPs.
Technology readiness level
The uncharged lipid delivery system has reached Technology Readiness Level 4, with successful synthesis and characterization of lipids and initial in vitro studies confirming cytotoxicity and immunogenicity profiles. Year 1 focuses on optimization and safety data collection, while Year 2 aims to expand in vivo studies and develop scalable manufacturing protocols to support commercialization.
About George Mason University
George Mason University is a large comprehensive public research university serving the Washington, DC region through campuses in Fairfax, Arlington, and Prince William County. Its Arlington site anchors an innovation district that co-locates faculty, startups, and corporate partners, while Fairfax and Prince William host shared core labs and specialized facilities. Proximity to federal agencies and the Northern Virginia technology corridor enables collaborative R&D, sponsored projects, and robust internship and hiring pipelines. The university also maintains a close partnership with a major regional health system to support clinical research and translational studies. Research is supported by competitive federal funding from agencies such as NSF, NIH, and the Department of Defense, and a dedicated technology transfer office with incubator programs streamlines IP, licensing, and startup formation.
delivered to your inbox.